Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis

Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP-NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA (p < 0.05), PP-NRS (p < 0.001), and IGA (p < 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large-scale, randomized controlled trials are necessary to confirm its long-term efficacy and safety.